Journal
NATURE COMMUNICATIONS
Volume 12, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-021-22580-8
Keywords
-
Categories
Funding
- National Institutes of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health (NIH)
- Vaccine Group Ltd
- University of Plymouth
Ask authors/readers for more resources
Orally administered nucleoside analog MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model, with an inhibitory effect observed whether the drug is given 12 hours before or 12 hours after infection. This suggests the potential of MK-4482 for controlling SARS-CoV-2 infection in humans following high-risk exposure and for treating COVID-19 patients.
The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12h before or 12h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients. While vaccines protecting against SARS-CoV-2 infection are approved, currently, there are no drugs suitable for high-risk exposure use against SARS-CoV-2. Here, Rosenke et al. provide evidence that orally delivered MK-4482, a nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available